GSK R&D chief Vallance is out as its new CEO changes direction under a new crew
Image: Patrick Vallance.
The R&D chief at GlaxoSmithKline is jumping ship, just as new CEO Emma Walmsley pushes through the final changes of a top-to-bottom shakeup aimed at spurring a more commercially effective strategy in drug development.
Patrick Vallance is turning in his company credentials in exchange for a new job in government, according to several reports out of London, with plans to take a job as a senior adviser to the government on science, though the Financial Times says that the current occupant of that job isn’t slated to leave for some months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.